These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 16634116)

  • 1. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin.
    Riddle MC; Henry RR; Poon TH; Zhang B; Mac SM; Holcombe JH; Kim DD; Maggs DG
    Diabetes Metab Res Rev; 2006; 22(6):483-91. PubMed ID: 16634116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
    Buse JB; Klonoff DC; Nielsen LL; Guan X; Bowlus CL; Holcombe JH; Maggs DG; Wintle ME
    Clin Ther; 2007 Jan; 29(1):139-53. PubMed ID: 17379054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.
    Blonde L; Klein EJ; Han J; Zhang B; Mac SM; Poon TH; Taylor KL; Trautmann ME; Kim DD; Kendall DM
    Diabetes Obes Metab; 2006 Jul; 8(4):436-47. PubMed ID: 16776751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.
    Buse JB; Henry RR; Han J; Kim DD; Fineman MS; Baron AD;
    Diabetes Care; 2004 Nov; 27(11):2628-35. PubMed ID: 15504997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
    Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
    Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
    Moretto TJ; Milton DR; Ridge TD; Macconell LA; Okerson T; Wolka AM; Brodows RG
    Clin Ther; 2008 Aug; 30(8):1448-60. PubMed ID: 18803987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary.
    Iványi T; Fövényi J; Faludi P; Han J; Macconell L; Wille S; Kiljanski J
    Clin Ther; 2012 Jun; 34(6):1301-13. PubMed ID: 22608106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
    Buse JB; Rosenstock J; Sesti G; Schmidt WE; Montanya E; Brett JH; Zychma M; Blonde L;
    Lancet; 2009 Jul; 374(9683):39-47. PubMed ID: 19515413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea.
    Gao Y; Yoon KH; Chuang LM; Mohan V; Ning G; Shah S; Jang HC; Wu TJ; Johns D; Northrup J; Brodows R
    Diabetes Res Clin Pract; 2009 Jan; 83(1):69-76. PubMed ID: 19019476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus.
    Ratner RE; Maggs D; Nielsen LL; Stonehouse AH; Poon T; Zhang B; Bicsak TA; Brodows RG; Kim DD
    Diabetes Obes Metab; 2006 Jul; 8(4):419-28. PubMed ID: 16776749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study.
    Yuan GH; Song WL; Huang YY; Guo XH; Gao Y
    Chin Med J (Engl); 2012 Aug; 125(15):2677-81. PubMed ID: 22931974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.
    Norwood P; Liutkus JF; Haber H; Pintilei E; Boardman MK; Trautmann ME
    Clin Ther; 2012 Oct; 34(10):2082-90. PubMed ID: 23031623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
    DeFronzo RA; Ratner RE; Han J; Kim DD; Fineman MS; Baron AD
    Diabetes Care; 2005 May; 28(5):1092-100. PubMed ID: 15855572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.
    Nauck MA; Duran S; Kim D; Johns D; Northrup J; Festa A; Brodows R; Trautmann M
    Diabetologia; 2007 Feb; 50(2):259-67. PubMed ID: 17160407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.
    Kendall DM; Riddle MC; Rosenstock J; Zhuang D; Kim DD; Fineman MS; Baron AD
    Diabetes Care; 2005 May; 28(5):1083-91. PubMed ID: 15855571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study.
    Poon T; Nelson P; Shen L; Mihm M; Taylor K; Fineman M; Kim D
    Diabetes Technol Ther; 2005 Jun; 7(3):467-77. PubMed ID: 15929678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.
    Zinman B; Hoogwerf BJ; Durán García S; Milton DR; Giaconia JM; Kim DD; Trautmann ME; Brodows RG
    Ann Intern Med; 2007 Apr; 146(7):477-85. PubMed ID: 17404349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin.
    Liutkus J; Rosas Guzman J; Norwood P; Pop L; Northrup J; Cao D; Trautmann M
    Diabetes Obes Metab; 2010 Dec; 12(12):1058-65. PubMed ID: 20977576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.
    Wysham C; Bergenstal R; Malloy J; Yan P; Walsh B; Malone J; Taylor K
    Diabet Med; 2011 Jun; 28(6):705-14. PubMed ID: 21434995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide].
    Pujante Alarcón P; Hellín Gil MD; Román LM; Ferrer Gómez M; García Zafra MV; Tébar Massó J
    Med Clin (Barc); 2012 Dec; 139(13):572-8. PubMed ID: 22209597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.